Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer-Reference-Cited by-同舟云学术

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Published:2023-03 Issue: Volume:170 Page:241-247
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Gilbert Lucy,Oaknin Ana,Matulonis Ursula A.,Mantia-Smaldone Gina M.,Lim Peter C.,Castro Cesar M.,Provencher Diane,Memarzadeh Sanaz,Method Michael,Wang Jiuzhou,Moore Kathleen N.,O'Malley David M.

Funder

ImmunoGen

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference27 articles.

1. Treatment of epithelial ovarian cancer;Kuroki;BMJ,2020

2. Management strategies for recurrent platinum-resistant ovarian cancer;Naumann;Drugs.,2011

3. “platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?;Davis;Gynecol. Oncol.,2014

4. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer;Haunschild;Future Oncol.,2020

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature;Gynecologic Oncology Reports;2024-10

2. Ecological and evolutionary dynamics to design and improve ovarian cancer treatment;Clinical and Translational Medicine;2024-08-29

3. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer;Future Oncology;2024-07-31

4. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

5. Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer;Cancers;2024-07-15